---
title: "MIST: CARDAMYST prescriptions and coverage surged post-launch, with strong clinical and regulatory momentum"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295658630.md"
description: "CARDAMYST's U.S. launch drove rapid prescription and coverage growth, with over 50% of commercially insured lives now covered. Q2 2026 saw increased revenue but higher net loss due to launch costs. Phase 3 AFib-RVR trial and regulatory reviews in Europe and China are progressing.Original document: Milestone Pharmaceuticals Inc. [MIST] Earnings Release — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T11:38:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295658630.md)
  - [en](https://longbridge.com/en/news/295658630.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295658630.md)
generator: "portal-rs"
---

# MIST: CARDAMYST prescriptions and coverage surged post-launch, with strong clinical and regulatory momentum

CARDAMYST's U.S. launch drove rapid prescription and coverage growth, with over 50% of commercially insured lives now covered. Q2 2026 saw increased revenue but higher net loss due to launch costs. Phase 3 AFib-RVR trial and regulatory reviews in Europe and China are progressing.

Original document: Milestone Pharmaceuticals Inc. \[MIST\] Earnings Release — Aug. 12 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MIST.US](https://longbridge.com/en/quote/MIST.US.md)

## Related News & Research

- [Milestone Pharmaceuticals enrolls first patient in Phase 3 ReVeRA-301 trial of etripamil nasal spray for AFib-RVR](https://longbridge.com/en/news/296615047.md)
- [Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update | MIST Stock News](https://longbridge.com/en/news/295655603.md)
- [NSIS_B: Raised full-year sales growth outlook to 7-8% and launched a EUR 1 billion share buyback](https://longbridge.com/en/news/296377920.md)
- [Why Data Center Moratoriums Won’t Derail the $7 Trillion AI Boom](https://longbridge.com/en/news/296650138.md)
- [Filevine launches 90-day free trial for LOIS legal AI system](https://longbridge.com/en/news/296383497.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**